This large-scale pan-cancer study of nearly 69,000 tumor-normal pairs profiled by MSK-IMPACT characterizes the biological and clinical implications of SMARCA4 alterations across functional mutation classes and allelic configurations. SMARCA4 alterations were most frequently observed in thymic epithelial tumors (10.7%), non-small cell lung cancer (7.1%), bladder cancer (5.6%), and cervical cancer (5%). Distinct profiles of genomic complexity, co-mutations, and mutational signatures were associated with specific allelic states (monoallelic vs. biallelic) and mutation classes (class 1 vs. class 2). Preliminary data from a phase I trial of the BRM degrader PRT3789 revealed clinical benefit, including one complete response, among patients harboring monoallelic class 2 SMARCA4 alterations with preserved BRG1 expression.
This study characterized the prevalence of KRAS G12C mutations in genitourinary malignancies, an area with limited data despite the approval of targeted therapies. Comprehensive genomic profiling was performed on over 13,000 samples of renal clear cell carcinomas, urothelial bladder carcinomas, and prostate acinar adenocarcinomas. Results indicated that KRAS G12C mutations are infrequent in these tumors, with an incidence of 0% in renal carcinomas, 0.6% in urothelial bladder carcinomas, and less than 0.01% in prostate adenocarcinomas. Despite their low frequency, these mutations represent an emerging therapeutic target, warranting further investigation, particularly in basket trials for patients harboring this actionable alteration.
This article outlines the protocol for an umbrella review aiming to synthesize evidence on prognostic biomarkers in bladder cancer. The objective is to compare all identified prognostic biomarkers in the literature to assess their clinical value. The authors plan to search systematic reviews and meta-analyses across multiple databases, extract relevant data, and assess the risk of bias. Statistical analysis will include pooled HR estimation, evaluation of heterogeneity and small-study effects, and an assessment of evidence credibility.
This study performed an integrated multi-omic analysis on a cohort of 48 bladder cancer patients to explore the molecular mechanisms of disease progression. Researchers identified frequent and active somatic LINE-1 (L1) insertions occurring early in cancer development. These L1 insertions are linked to downstream genomic rearrangements, chromosomal instability, and an increase in structural variants and extrachromosomal DNA (ecDNA). The study proposes a model where L1 retrotransposition triggers genomic instability and a viral mimicry response.
This study investigates predictive biomarkers for immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma. Researchers found that ICI responders exhibited higher tumor mutational burden (TMB) and enriched mutations in genes such as PIK3CA. Functional in vitro and in vivo studies demonstrated that PIK3CA mutations enhance tumor immunogenicity by activating the IRF1-NLRC5-MHC-I axis, thereby improving antigen presentation and CD8+ T-cell cytotoxic response. These findings suggest that PIK3CA mutation could serve as a biomarker to predict ICI sensitivity and represents a novel immune-modulating mechanism.
The prospective phase 2 DUTRENEO study demonstrated that a retrospectively validated 18-gene tumor inflammation signature (TIS) failed to predict response to neoadjuvant immune checkpoint inhibitors (ICIs) in muscle-invasive bladder cancer. This outcome indicates that bulk gene-expression stratification is insufficient to enrich for responders. Single-cell spatial transcriptomic analysis revealed that response is instead governed by spatial architectures, such as CD8+ T cell proximity to cancer cells and localized checkpoint co-expression, which are invisible to bulk assays. A quantitative framework was developed, suggesting that at least 77 genes and tissue regions of at least 3-mm diameter are required to preserve predictive spatial signals.
This retrospective study investigated the frequency and molecular profiles of PAX8-positive conventional urothelial carcinomas (UCs) of the urinary bladder. Out of 101 cases, 10% were found to be PAX8-positive by immunohistochemistry. Next-generation sequencing (NGS) was performed on 20 cases, including all PAX8-positive UCs. The findings revealed that PAX8-positive UCs frequently harbored TERT promoter mutations, TSC1 alterations, NOTCH1 loss, and WT1 loss, while notably lacking RB1 loss, distinguishing them from PAX8-negative UCs. These results indicate a distinct molecular signature for PAX8-positive UCs, emphasizing the need for careful diagnostic interpretation of PAX8.